Phase 2 Breast Cancer Trial, Recruiting NCT04430595 Sponsor: Shenzhen Geno-Immune Medical Institute Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Recruiting

NCT04430595
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with stage III, stage IV, or relapsed breast cancer, confirmed through tissue testing and biopsy.
  • People who are aged 18 to 75 years old.
  • People who have waited at least 2 weeks since their last chemotherapy or radiation treatment, and at least 2 weeks since last taking steroid or immune-suppressing medicines.
  • People whose side effects from chemotherapy have settled down.
  • People whose cancer cells test positive for certain target proteins — GD2, CD44v6, or Her2 — based on laboratory testing of tumour tissue.
  • People with a good general level of physical functioning, meaning they are fully active or able to carry out light work (confirm with trial site for exact definition).
  • People whose doctors expect them to survive for at least 12 weeks.
  • People whose blood counts and bone marrow function meet minimum levels set by the trial (confirm with trial site for exact values).
  • People whose kidney and liver function test results fall within the ranges required by the trial.
  • People whose blood oxygen level is 90% or above.
  • People who are willing and able to give written consent before any trial procedures begin.

Who may not be able to join:

  • People whose tumour is blocking their airway.
  • People with a history of epilepsy or other conditions affecting the brain or nervous system.
  • People who need to take steroid medicines or other immune-suppressing treatments on an ongoing basis.
  • People with a history of serious heart rhythm problems involving a prolonged QT interval (confirm with trial site for exact definition).
  • People who have taken part in another clinical trial or received an experimental drug within the 28 days before the trial start date, or who have previously been in this study.
  • People whose kidney or liver function test results fall outside the limits set by the trial.
  • People who are pregnant or breastfeeding.
  • People who have a serious active infection at the time of screening.
  • People with an active HIV, hepatitis B, or hepatitis C infection, or any infection that is not under control.
  • People who, in the opinion of the trial doctors, may not be suitable or may have difficulty following the study requirements.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86 0755-86573763

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Shenzhen Geno-Immune Medical Institute
Registry
ClinicalTrials.gov
Start date
1 June 2026
Est. completion
31 December 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Number of patients with adverse events.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov